A promising cardiovascular treatment in a highly prevalent disease

A highly prevalent disease with existing inexpensive therapies presented a challenging pricing environment for our client’s cardiovascular treatment. To deliver the optimal pricing strategy, Inpharmation used a combination of primary and secondary pricing techniques.


Back to Case Studies

Our client wanted to understand the optimal pricing strategy…

Our client was developing a potential breakthrough in the treatment for heart failure. They wanted to understand the optimal pricing strategy across the EU5 and the USA.

...but the pricing environment was challenging

Although our client’s asset promised to deliver significant clinical benefits, there were challenges. Firstly, existing therapies were inexpensive. Secondly, heart failure is a very common condition. Both of these considerations would put downward pressure on price, so pricing was not without risk.

Our client wanted to:

  • Understand the impact of clinical results from different patient subgroups.
  • Inform national, regional and local pricing strategy.
  • Quantify the usage in different channels:
    • Specialist vs. primary care physicians.
    • Retail vs. hospital.

 

Download the full Case Study by filling in the form:

By clicking on the “Submit Request” button you are providing consent for us to store your data and contact you. You may withdraw your consent at any time by instructing us at .

View our Privacy Policy for more information.

Please note that Inpharmation literature and case study materials constitute Inpharmation intellectual property and are intended for the pharmaceutical industry. Inpharmation is under no obligation to distribute these materials to non-pharmaceutical industry employees or competitors.

Scroll Top